Skip to main content

Table 1 Demographic and disease-specific characteristics in the three treatment subgroups

From: Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients

  No DMARDs, N = 79 bDMARD, N = 52 Methotrexate, N = 34 p value a/b/c
Demographic characteristics
 Sex (M/F) 31/48 29/23 17/17 −/−/−
 Age, (mean ± SD) 49.3 ± 12.0 48.0 ± 11.7 50.9 ± 11.3 −/−/−
 Body mass index, (mean ± SD) 28.6 ± 6.2 29.0 ± 6.0 28.8 ± 6.4 −/−/−
 Smokers, N (%) 24 (30) 12 (23) 7 (21) −/−/−
 Menopause, N (%) 21 (27) 12 (23) 7 (21) −/−/−
 Previous fracture, N (%) 4 (5) 2 (4) 2 (6) −/−/−
Disease-specific characteristics
 Duration of PSO (years), (mean ± SD) 18.1 ± 16.1 20.2 ± 11.1 20.3 ± 16.4 −/−/−
 Duration of PsA (years), (mean ± SD) 2.9 ± 5.2 7.8 ± 7.4 4.6 ± 7.4 < 0.001/0.011/0.018
 MDA, N (%) 28 (35) 25 (48) 22 (65) −/0.004/
 DAPSA
  DAPSA score, (mean ± SD) 17.0 ± 11.4 12.3 ± 9.6 15.8 ± 17.8 0.009/−/−
  Remission, N (%) 7 (9) 10 (19) 6 (18) −/−/−
  Low activity, N (%) 29 (37) 25 (48) 13 (38) −/−/−
  Moderate activity, N (%) 24 (30) 12 (23) 9 (27) −/−/−
  High activity, N (%) 12 (15) 2 (4) 4 (12) 0.040/−/−
 Nail involvement, N (%) 20 (25) 7 (14) 8 (24) −/−/−
 Scalp involvement, N (%) 35 (44) 8 (15) 8 (24) 0.002/−/−
 PASI (units), (mean ± SD) 4.0 ± 4.7 1.2 ± 2.7 2.1 ± 7.9 < 0.001/0.001/−
 DLQI (units), (mean ± SD) 7.5 ± 6.5 3.2 ± 5.3 6.0 ± 5.3 0.043/−/−
 HAQ (units), (mean ± SD) 0.6 ± 0.5 0.5 ± 0.5 0.7 ± 0.8 −/−/−
 Diabetes mellitus, N (%) 2 (3) 3 (6) 2 (6) −/−/−
 Hypertension, N (%) 19 (24) 14 (27) 5 (15) −/−/−
Autoantibody status
 Positive low-titer ACPA, N (%)* 1 (1) 0 1 (3) −/−/−
 Positive low-titer RF, N (%)** 3 (4) 0 1 (3) −/−/−
Anti-rheumatic and bone treatments
 Vitamin D supplementation, N (%) 10 (13) 11 (21) 9 (27) −/−/−
 Bisphosphonates, N (%) 0 1 (2) 0 −/−/−
 Current glucocorticoids, N (%) 0 6 (12) 5 (15) 0.002/0.001/−
 Former glucocorticoids intake, N (%) 4 (5) 13 (25) 5 (15) 0.001/−/−
 Duration of glucocorticoids intake (years), (mean ± SD) 1.1 ± 1.0 2.8 ± 2.2 0.4 ± 0.2 −/−/0.034
  1. Bonferroni-Holm adjustment: critical p values indicating significant results (italicize p values) for all investigated parameters were as follows: p1 = 0.0167, p2 = 0.025, p3 = 0.05
  2. ACPA anti-citrullinated protein antibody, bDMARDs biologic disease-modifying anti-rheumatic drugs, N number, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, PSO psoriasis, MDA minimal disease activity, DAPSA Disease Activity Index for Psoriatic Arthritis, DLQI Dermatology Life Quality Index, HAQ health assessment questionnaire, RF rheumatoid factor, a no therapy vs. bDMARD, b no therapy vs. methotrexate, c bDMARD vs. methotrexate
  3. *< 20 U/mL; **> 50 IE/mL
  4. Fracture in adult life that occured spontaneously, or fractures caused by trauma that would not have led to a fracture in a healthy person
  5. a no therapy vs. bDMARD
  6. b no therapy vs. Methotrexate
  7. c bDMARD vs. methotrexate